Background: Hypertensive patients with normal glucose tolerance (NGT) but 1-h post load
plasma glucose >155 mg/dl (1-h high), during the oral glucose tolerance test (OGTT), show an
unfavorable metabolic profile characterized by higher insulin resistance (IR), subclinical
inflammation and multiple target organ damage. Experimental and clinical studies have
demonstrated that silybin presents important anti-inflammatory and metabolic effects,
improving IR and endothelial dysfunction. The present study aims to evaluate the effects of
the complex silybin-vitamin E and phospholipids on inflammatory, metabolic and vascular
parameters in NGT 1-h high hypertensive patients.
Methods: This is a pilot, single arm, interventional, longitudinal study in which the
investigators have planned to enroll 50 Caucasian never-treated hypertensive outpatients,
showing normal glucose tolerance but 1-h post load plasma glucose >155 mg/dl, during the
OGTT.